Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | MITF | O75030 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | UBE2N | P61088 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11178443 | 1.00 | CYP3A4 (1.00) | CYP3A4TSHRHSD17B10GAAMAPT | |
| SCHEMBL6207027 | 0.86 | CYP3A4 (0.75) | CYP3A4TSHRHSD17B10GAAMAPT | |
| SCHEMBL11184367 | 0.86 | CYP3A4 (0.75) | CYP3A4TSHRHSD17B10GAAALDH1A1 | |
| SCHEMBL11184849 | 0.86 | CYP3A4 (0.75) | CYP3A4TSHRHSD17B10TP53ALDH1A1 | |
| SCHEMBL1000486 | 0.84 | POLB (0.74) | CYP3A4TSHRHSD17B10MAPTKDM4E | |
| SCHEMBL1708867 | 0.84 | TSHR (1.00) | CYP3A4TSHRHSD17B10MAPTKDM4E | |
| SCHEMBL11178290 | 0.83 | CYP3A4 (0.71) | CYP3A4TSHRHSD17B10GAAKDM4E | |
| SCHEMBL11179498 | 0.83 | CYP3A4 (0.71) | CYP3A4TSHRHSD17B10GAAKDM4E | |
| SCHEMBL4717672 | 0.82 | TSHR (0.72) | CYP3A4TSHRHSD17B10GAAMAPT | |
| SCHEMBL11825142 | 0.82 | TSHR (0.72) | CYP3A4TSHRHSD17B10MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-20070021606-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021606-A1 | Therapeutic compounds | GRIN1, GRIN3A, GRM2 | CYP3A4 3976/4885TSHR 685/4885HSD17B10 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.